Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02126969 · ClinicalTrials.gov registry record · Phase 2
A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN
A Phase 2 study, sponsored by Susanne Arnold.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT02126969 is a Phase 2 study that has completed, run by Susanne Arnold. The registered enrollment target is 45 participants.
The verdict
NCT02126969, a Phase 2 study, has completed, sponsored by Susanne Arnold.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The primary hypothesis of this study is that hyper-radiosensitivity (HRS) seen at extremely low doses of radiation can be exploited to enhance the effect of chemotherapy, and that this effect differs from the cellular effect of higher, standard fractions of radiation used in traditional radiation treatment paradigms.
Interventions
- RADIATION Low dose fractionated radiation - 80cGy with chemotherapy
- DRUG Docetaxel and Carboplatin AUC 6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-10 |
| Est. Completion | 2021-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02126969
The ClinicalTrials.gov registry entry for NCT02126969 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Susanne Arnold, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Low dose fractionated radiation - 80cGy with chemotherapy is the first listed.
NCT02126969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02126969 about?
NCT02126969 is a clinical study titled "A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN". The primary hypothesis of this study is that hyper-radiosensitivity (HRS) seen at extremely low doses of radiation can be exploited to enhance the effect of chemotherapy, and that this effect differs from the cellular effect of higher, standard fractions of radiation used in traditional radiation tr...
What is the current status of trial NCT02126969?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2014-10. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT02126969?
The interventions under investigation include: Low dose fractionated radiation - 80cGy with chemotherapy (RADIATION), Docetaxel and Carboplatin AUC 6 (DRUG).
Who is sponsoring clinical trial NCT02126969?
This trial is sponsored by Susanne Arnold, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.